CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH According to the SUSTAIN FORTE study presented online in The Lancet Diabetes & Endocrinology, doubling the dose of semaglutide (Ozempic) might be a helpful option for people not achieving glycemic goals. Still, some researchers aren’t convinced this is a sound strategy – “statistically significant but barely clinically relevant” — suggesting opting for another agent when faced with a patient struggling to control HbA1c.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
